Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02YYF
|
|||
| Former ID |
DAP000939
|
|||
| Drug Name |
Bretylium
|
|||
| Synonyms |
Bretylum; Bretylium tolsylate; Bretylium tosylate(USAN); N-(2-bromobenzyl)-N,N-dimethylethanaminium; N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium; Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1); (2-bromobenzyl)ethyldimethylaminium; (2-bromophenyl)methyl-ethyl-dimethylazanium; (o-Bromobenzyl)ethyldimethylammonium p-toluenesulfonate; 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Ventricular fibrillation [ICD-11: BC71.1; ICD-10: I49, I49.0] | Approved | [1] | |
| Therapeutic Class |
Antiarrhythmic Agents
|
|||
| Company |
Hospira Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H17BrN+
|
|||
| Canonical SMILES |
CC[N+](C)(C)CC1=CC=CC=C1Br
|
|||
| InChI |
1S/C11H17BrN/c1-4-13(2,3)9-10-7-5-6-8-11(10)12/h5-8H,4,9H2,1-3H3/q+1
|
|||
| InChIKey |
AAQOQKQBGPPFNS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 59-41-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9073, 794516, 5580995, 7978814, 8151623, 11468090, 11486799, 14749639, 29221595, 46505320, 47365410, 47515523, 47515524, 48035343, 49699004, 50064953, 50113154, 50113155, 50310316, 57321311, 85209526, 92740966, 104300566, 126407358, 126729469, 127378478, 131273742, 134222665, 134338214, 135021960, 137001461, 142246611, 160964492, 162201420, 175267511, 178103706, 179225252, 223454297, 223518984, 223814627, 225144298, 226405825, 246089195
|
|||
| ChEBI ID |
CHEBI:3172
|
|||
| ADReCS Drug ID | BADD_D00292 | |||
| SuperDrug ATC ID |
C01BD02
|
|||
| SuperDrug CAS ID |
cas=000061756
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-1 (ADRB1) | Target Info | Antagonist | [2], [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Gap junction | ||||
| Salivary secretion | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta1 adrenergic receptor signaling pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Components of functional sympathetic control of heart rate in neonatal rats. Am J Physiol. 1985 May;248(5 Pt 2):R601-10. | |||
| REF 3 | Dissociation of autonomic controls of heart rate in weaning-aged borderline hypertensive rats by perinatal NaCl. J Auton Nerv Syst. 1990 Mar;29(3):219-26. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.